Clinical trials: Stage I Multiple Myeloma
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Solid Tumours, Multiple Myeloma
Phase I Trial of VS-6766 Alone and in Combination With Everolimus
This study is a multi-centre, investigator-initiated, Phase I clinical trial evaluating different dosing schedules of VS-6766, given either alone or in combination with everolimus, in patients with advanced solid tumours or…
- Conditions
- Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer
- Trial name
- RAF/MEK (NCT02407509)
- Testing
- VS-6766, Everolimus
- Where
- 3 sites in United Kingdom
- Volunteers
- 104 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Relapsed or Refractory Multiple Myeloma
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.
- Trial name
- NCT01866293
- Testing
- Cabozantinib (XL184)
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma
RATIONALE: Biological therapies, such as antithymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00378768
- Testing
- anti-thymocyte globulin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm, Renal Failure
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
RATIONALE: Dexamethasone is used to treat multiple myeloma. Drugs used in chemotherapy may stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416897
- Testing
- chemotherapy, dexamethasone, plasmapheresis
- Where
- 39 sites in United Kingdom
- Volunteers
- 280 people
- Sponsor
- University of Glasgow
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281879
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- OHSU Knight Cancer Institute
Infection, Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation and immunotherapy may allow the…
- Trial name
- NCT00046852
- Testing
- filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes
- Where
- 2 sites in United States
- Sponsor
- University of Maryland, Baltimore
Multiple Myeloma
BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.
- Trial name
- NCT03093168
- Testing
- Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Multiple Myeloma
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by…
- Trial name
- NCT01050790
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Virginia Commonwealth University
Multiple Myeloma
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or…
- Trial name
- NCT04557150
- Testing
- Forimtamig
- Where
- 20 sites in Australia, Belgium and 7 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
This phase II trial studies the side effects and how well bortezomib and pegylated liposomal doxorubicin hydrochloride work in treating patients multiple myeloma that are experiencing symptoms and have not received prior…
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
- Trial name
- NCT00088855
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial
To investigate the effect of an anti-inflammatory therapy consisting of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan on the response rate in patients with…
- Trial name
- MM03 (NCT01010243)
- Testing
- Lenalidomide, Pioglitazone, dexamethasone, treosulfan
- Where
- 6 sites in Germany
- Volunteers
- 54 people
- Sponsor
- University of Regensburg
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002548
- Testing
- recombinant interferon alfa, carmustine, cyclophosphamide
- Where
- 34 sites in United States
- Volunteers
- 899 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- IMGN901 (NCT00346255)
- Testing
- BB-10901
- Where
- 8 sites in United States, Argentina
- Volunteers
- 37 people
- Sponsor
- ImmunoGen, Inc.
Multiple Myeloma
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.
- Trial name
- NCT01122875
- Testing
- MFGR1877S
- Where
- 12 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
The combination of PARP inhibitor (ABT-888) with a proteasome inhibitors (bortezomib) have demonstrated significant anti-myeloma effects in preclinical lab and animal studies.
- Trial name
- NCT01495351
- Testing
- ABT-888/Bortezomib
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- AHS Cancer Control Alberta
Multiple Myeloma, Multiple Myeloma in Relapse
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
The goal of this clinical trial is to learn about the safety and efficacy of the drug combination belantamab mafodotin and venetoclax, with or without the addition of dexamethasone, in patients with relapsed/refractory multiple…
- Trial name
- BELI(E)VE (NCT05853965)
- Testing
- Belantamab mafodotin, Venetoclax
- Where
- 5 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Multiple Myeloma
CP-751,871 Treatment For Patients With Multiple Myeloma
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
- Trial name
- NCT01536145
- Testing
- CP-751,871
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Pfizer
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center